For Alzheimer's Agitation, Promising News from Rexulti (Brexpiprazole)

Rexulti (brexpiprazole) shares positive trial results for treating agitation in Alzheimer's. Following this a bumpy road for another Alzheimer's drug candidate that could supplant the need for antipsychotics to treat behavioral Alzheimer's symptoms, this could be the first such drug approved — if its safety and efficacy data stay on track.

Brexpiprazole (Rexulti) Approved for Alzheimer's Agitation

FDA Advisors Endorse Rexulti for Agitation in Alzheimer's Dementia

Prazosin Looks Promising for Agitation in Dementia [AlzWeek.com]

FDA Approves the First Drug for Alzheimer's Agitation: Rexulti

Not Everyone Agreed With FDA Approval of Antipsychotic Rexulti for

Brexpiprazole (Rexulti) Approved for Alzheimer's Agitation

Brexpiprazole (Rexulti): Uses, Side Effects, Warnings & More - GoodRx

FDA Approves First Drug to Treat Dementia-Associated Agitation in

JAMA Neurology Publishes Complete Results of Positive Phase 3

Otsuka and Lundbeck Announce U.S. Food and Drug Administration

BioXcel shares rise on result of Alzheimer's drug probe

Pharma News for Sarepta, Astellas, SiSaf, ImmPACT Bio, Otsuka